Showing results (331-340 of 427) with videos related to

Sort By:
Pageof 43
Cancer|March 3, 2018
Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinibFabio Efficace, Fausto Castagnetti, Bruno Martino, et al.
Haematologica|July 30, 2016
Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patientsFausto Castagnetti, Massimo Breccia, Gabriele Gugliotta, et al.
Haematologica|June 27, 2015
Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemiaGabriele Gugliotta, Fausto Castagnetti, Massimo Breccia, et al.
British Journal of Haematology|April 19, 2017
Iron-chelating therapy with deferasirox in transfusion-dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre studyPellegrino Musto, Luca Maurillo, Vittorio Simeon, et al.
British Journal of Haematology|October 2, 2014
Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromesFabio Efficace, Gianluca Gaidano, Massimo Breccia, et al.
Haematologica|April 7, 2022
Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 studyGabriele Gugliotta, Fausto Castagnetti, Massimo Breccia, et al.
Blood|July 14, 2011
Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general populationFabio Efficace, Michele Baccarani, Massimo Breccia, et al.
Blood|May 17, 2013
Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemiaDomenico Russo, Giovanni Martinelli, Michele Malagola, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 25, 2025
Disease Phenotype Significantly Influences the Outcome After Discontinuation of Ruxolitinib in Chronic Phase MyelofibrosisFrancesca Palandri, Massimo Breccia, Erika Morsia, et al.
International Journal of Cardiology|April 29, 2019
Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary preventionGiovanni Caocci, Olga Mulas, Massimiliano Bonifacio, et al.
Pageof 43